GlassScriptPhysician profile
Daniel Brandt
NPI 1700221603
$3,774.02
in general payments reported to CMS, 2019-2025
27 companies · $1,184 in 2025
The $1,184 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.22 · 2020: $99.65 · 2021: $301 · 2022: $486 · 2023: $645 · 2024: $962 · 2025: $1,184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,790.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,790.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $660.72 | 2020-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $552.59 | 2020-2025 | Entyvio |
| Abbvie INC. | $540.53 | 2019-2025 | Linzess, Rinvoq, Skyrizi |
| Qol Medical, LLC | $337.04 | 2023-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $247.22 | 2024-2025 | Ibsrela |
| Genzyme Corporation | $189.60 | 2023-2025 | |
| Janssen Biotech, INC. | $178.64 | 2021-2025 | Stelara, Simponi Aria, Tremfya |
| Boston Scientific Corporation | $176.76 | 2019-2024 | Exalt Model D, Watchman |
| Lilly USA, LLC | $134.84 | 2024-2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $133.40 | 2020-2024 | Linzess |
| E.R. Squibb & Sons, L.L.C. | $96.49 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $71.61 | 2023-2024 | Dupixent |
| Braintree Laboratories, INC. | $59.65 | 2023-2024 | Sutab, Suflave |
| Celltrion USA INC. | $54.64 | 2025 | Vegzelma |
| Pfizer INC. | $46.49 | 2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $43.49 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $43.33 | 2024-2025 | Resmetirom, Rezdiffra |
| Daiichi Sankyo INC. | $42.96 | 2022-2023 | Injectafer |
| Romark Laboratories, Lc | $29.21 | 2020 | |
| Redhill Biopharma INC. | $27.83 | 2021 | |
| Endogastric Solutions, INC | $17.90 | 2024 | Esophyx |
| Ge Healthcare | $16.82 | 2025 | |
| Phathom Pharmaceuticals, INC. | $16.31 | 2024 | Voquezna |
| Evoke Pharma, INC. | $15.99 | 2023 | Gimoti |
| Erbe USA INC | $15.00 | 2022-2025 | Vio 3 |
| W. L. Gore & Associates, INC. | $12.78 | 2021 | |
| Gilead Sciences, INC. | $12.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Brandt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.